High Dose Inspiratory Muscle Training in LOPD
Study Details
Study Description
Brief Summary
Study Objectives: 1) assess the safety and feasibility of high-dose inspiratory muscle training (IMT) delivered remotely in Late-onset Pompe Disease (LOPD) and 2) determine its effects on respiratory and patient-reported outcomes.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
This study aims to develop treatments that enhance respiratory strength and function to provide meaningful clinical improvements for people with LOPD. Identification of a cost-effective adjunctive intervention to address respiratory weakness remains critical to reduce disease burden, ease activity limitations and participation restrictions, and improve health-related quality of life. The proposed study will provide a high-dose inspiratory muscle training (IMT) stimulus to enhance treatment efficacy and efficiency. Our hypothesis is that high-dose IMT is necessary to produce meaningful changes in respiratory muscle strength and other outcomes in participants with LOPD.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: High Dose Inspiratory Muscle Training Inspiratory Muscle Training 3 times a week over 26 weeks |
Device: IMT therapy using the Pr02 mobile device
Inspiratory Muscle Training using a device used to measure and increase respiratory strength and performance through resisted breathing exercises.
|
Outcome Measures
Primary Outcome Measures
- Change in maximum inspiratory pressure (MIP) [Baseline, week 15, week 30]
Change pre-test to post test, measured in cm H20
Secondary Outcome Measures
- Change in maximum expiratory pressure (MEP) [Baseline, week 15, week 30]
Change pre-test to post test, measured in cm H20
- Change in inspiratory power curve (IPC) [Baseline, week 15, week 30]
Change pre-test to post test, measured in pressure-time units (PTUs)
- Change in inspiratory duration (ID) [Baseline, week 15, week 30]
Change pre-test to post test, measured by duration in seconds
- Change in fatigue index test score (FIT) [Baseline, week 15, week 30]
Change pre-test to post test, a proprietary measure which quantifies propensity to inspiratory muscle fatigue based upon the relationship between inspiratory capacity and demand using the following equation: (IPC [in Watts] x MID) / (Power500 x T500), where Power500 = power expended to inspire a mass of 500 mL air and T500 = time when mass of inspired air=500 mL at sea level
- Change in forced vital capacity (FVC) [Baseline, week 15, week 30]
Change pre-test to post-test, measured in liters using a portable hand-held spirometer
- Change in forced expiratory volume over 1 second (FEV1) [Baseline, week 15, week 30]
change pre-test to post-test, measured in liters per second using a portable hand-held spirometer
- Change in peak expiratory flow (PEF) [Baseline, week 15, week 30]
change pre-test to post-test, measured in liters per second using portable hand-held spirometer
- Change in inspiratory phase duration (IPD) [Baseline, week 15, week 30]
change pre-test to post-test, measured in seconds
- Change in inspiratory peak flow (IPF) [Baseline, week 15, week 30]
Change pre-test to post-test, measured in liters per second
- Change in compression phase duration (CPD) [Baseline, week 15, week 30]
Change pre-test to post-test, measured in seconds
- Change in expiratory phase rise time (EPRT) [Baseline, week 15, week 30]
Change pre-test to post-test, measured in liters per second
- Change in cough volume acceleration (CVA) [Baseline, week 15, week 30]
Change pre-test to post-test, measured by EPF/EPRT
- Change in fatigue [Baseline, week 15, week 30]
Change pre-test to post-test, measured by Fatigue Severity Scale (FSS) survey completion, using a 7 point ordinal scale where a rating of 1 indicates strong disagreement and a rating of 7 indicates strong agreement.
- Change in impact of fatigue on quality of life (QOL) [Baseline, week 15, week 30]
Change pre-test to post-test, measured by Modified Fatigue Impact Scale (MFIS) survey completion using a score of 0 (never affected) to 4 (almost always affected). The total score ranges from 0 to a maximum of 84. Higher scores indicate greater impact of fatigue on quality of life.
- Change in daytime sleepiness [Baseline, week 15, week 30]
Change pre-test to post-test, measured by Epworth Sleepiness Scale (ESS) survey completion using a 0 to 3 ordinal scale in which 0=no chance of dozing, 1=slight chance of dozing, 2= moderate chance of dozing, and 3=high chance of dozing. Scores are summed to obtain total ESS score where a score >10 reflects excessive daytime sleepiness.
- Change in sleep quality [Baseline, week 15, week 30]
Change pre-test to post-test, measured by Pittsburgh Sleep Quality Index (PSQI) survey completion. The PSQI is a 9-question, 19-item instrument. Items 1 to 4 are open-ended questions (customary bedtime, length of time to fall asleep). Items 5 to 8 (including the 10 questions comprising item 5) are sleep symptoms which are rated as to their frequency using an ordinal scale: 0=not occurring in the last month, 1=less than once a week, 2=once or twice a week, and 3=three or more times a week. Item 9 is a rating of overall sleep quality over the past month using a 0 to 3 ordinal scale: 0=very good; 1=fairly good; 2= fairly bad; and 3=very bad. Scores from the 19-items are combined according to standard scoring criteria to obtain a Global PSQI score. Scores >5 indicate reduced sleep quality.
- Change in respiratory symptoms [Baseline, week 15, week 30]
Change pre-test to post-test, measured by Respiratory Symptoms Questionnaire (RSQ) completion using a 0-3 scale where a higher score indicates worse symptoms.
- Change in motor performance [Baseline, week 15, week 30]
Change pre-test to post-test, measured by Rotterdam Handicap Scale (RHS) survey completion using a ranging scale of 1 - 4 where 1 = unable to fulfil the task or activity and 4 = complete fulfillment of the task or activity. Scores are summed and range from 9-36.
- Change in health-related quality of life [Baseline, week 15, week 30]
Change pre-test to post-test, measured by Short Form 36 (SF-36) survey completion where physical and mental component summary scales (PCS and MCS) are calculated from the subscales and transformed to a normalized T-score with a mean of 50 and a standard deviation of 10. Higher scores represent better health-related quality of life.
- Change in ability to communicate [Baseline, week 15, week 30]
Change pre-test to post-test, measured by Communicative Participation Item Bank-Short From (CPIB-10) survey completion using a 4-point scale (not at all=3, a little=2, quite a bit=1, very much=0). Item scores are added to obtain the summary score which ranges from 0-30. This can be transformed into a standard T score (mean=50, SD=10). Higher scores represent less interference in communication participation.
- Change in voice quality [Baseline, week 15, week 30]
Change pre-test to post-test, measured by Voice Handicap Index (VHI-10) survey completion using a 5-point scale (0=never, 1=almost never, 2=sometimes, 3=almost always, 4=always). Item responses are added to obtain a total score (values >11 abnormal) with higher scores indicating greater perception of voice-related handicap.
- Change in swallowing symptoms [Baseline, week 15, week 30]
Change pre-test to post-test, measured by Eating Assessment Tool (EAT-10) survey completion using a 5-point scale (0=no problem, 4=severe problem). Item responses are added to obtain a total score (values >3 abnormal) with higher scores indicating greater severity of swallowing symptoms.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥ 18 years
-
Confirmed diagnosis of LOPD
-
MIP >50% of predicted for sex and age
-
Stable on current Pompe disease treatment regimen >6 months
-
Able to follow directions for study participation
-
Access to computer and smartphone/tablet with reliable internet connection for video visits and sensor-based respiratory technologies
Exclusion Criteria:
-
Presence of medical comorbidities that prevent meaningful study participation (e.g., COPD GOLD III-IV, significant mental illness, dementia)
-
Use of continuous invasive or non-invasive ventilation while awake
-
Prior history of gene therapy for LOPD
-
Inability to give legally effective consent
-
Inability to read and understand English
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Duke University Medical Center | Durham | North Carolina | United States | 27705 |
Sponsors and Collaborators
- Duke University
- Genzyme, a Sanofi Company
Investigators
- Principal Investigator: Harrison Jones, PhD, Duke University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Pro00109392